循环微RNA作为潜在的喘诊断工具,并用于指示严重喘风险
Elena V Vorobeva1, M Aref Kyyaly2, Collin L Sones3,4
1Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
International journal of molecular sciences
|July 29, 2025
概括
血清微RNAs (miRNAs) 显示出作为喘生物标志物的前景. 特定miRNA的面板可以帮助诊断喘并预测其严重程度,改善患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 肺部病理学 肺部病理学
背景情况:
- 喘诊断缺乏一个黄金标准的客观测试.
- 生物标志物是需要准确的喘诊断和严重程度预测.
- 微RNAs (miRNAs) 正在成为潜在的疾病生物标志物.
研究的目的:
- 开发用于喘诊断的血清miRNA面板.
- 为了确定miRNA面板来预测喘严重程度.
- 评估miRNA生物标记物的诊断和预后价值.
主要方法:
- 从从未患过喘,轻度喘和严重喘患者的血清中选了35种喘相关的miRNA.
- 使用了miRCURY LNA技术和GeneGlobe分析.
- 评估了miRNA表达与临床结果和诊断价值的关联.
主要成果:
- 一个喘诊断小组 (miR-223-3p,miR-191-5p,miR-197-3p) 显示AUC=0.813,灵敏度=76%,特异性=72%.
- 一个喘严重程度小组 (miR-223-3p,miR-30a-5p,miR-660-5p,miR-125b-5p) 显示AUC=0.759,敏感度=78%,特异性=64%.
- 个别miRNA与喘严重程度和生活质量下降相关.
结论:
- 血清miRNA面板显示出作为敏感和特定生物标记物的潜力.
- 这些小组可以帮助客观地诊断喘和预测严重性风险.
- 进一步验证可能会导致基于miRNA的喘评估的临床应用.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464
01:29Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K